ArticleCardiovascular engineering and technology2025
Computational Simulations Show Proof-of-Concept for Optogenetic Suppression of Ectopic Activity in Cardiac Stem Cell Therapy.
Article in Cardiovascular engineering and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeMyocardial infarction results in extensive cardiac remodeling that can lead to heart failure. Human pluripotent stem cell-derived cardiomyocyte (hPSC-CM) injection can improve heart function but may lead to engraftment-associated ventricular tachycardia (VT). Optogenetics uses light stimulation to control electrical activity of cells genetically modified to express light-sensitive proteins (opsins). This study aims to use computational simulations to test the feasibility of optogenetically suppressing hPSC-CM ectopic activity without inhibiting the ability to undergo excitation by upstream wavefronts (i.e., engrafted cells could activate harmoniously with surrounding host myocardium during propagation of a normal sinus beat).
methodsWe simulated electrophysiology in single-cell hPSC-CM and tissue-scale ventricular models derived from histology images. The latter comprised host myocardium, hPSC-CM graft, and non-conductive scar. Ventricular and hPSC-CM cellular models were used in the host myocardium and hPSC-CM graft regions, respectively. Optogenetic modification of hPSC-CMs was simulated via incorporation of a photocycle model with the approximate properties of WiChR, a light-sensitive potassium channel. To test the efficacy of the proposed approach for silencing graft activity, we simulated sustained blue light illumination at 488 nm.
resultsSustained optogenetic stimulation suppressed spontaneous excitation altogether in opsin-expressing hPSC-CM models while maintaining cellular excitability. At the tissue scale, optogenetic suppression of VT-associated ectopic excitations was feasible with epicardial illumination. Opsin-expressing grafts in optogenetically silenced histology models remained excitable under simulated sinus rhythm-like excitation from the endocardium; however, potentially arrhythmogenic spatial heterogeneity of action potential duration was seen in model geometries with greater wall thickness.
conclusionsOur simulations suggest WiChR-based optogenetic suppression of hPSC-CM graft-associated arrhythmia is likely feasible but must be carefully calibrated to avoid inadvertently pro-arrhythmic side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.